OpenAlex
PricingAboutJobs
Log inGet started
Work

Updated 5-year Survival Results from PURE-01, a Phase 2 Study of Neoadjuvant Pembrolizumab Followed by Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer

HTML

Year: 2026
Type: article
Source: European Urology
DOI: 10.1016/j.eururo.2026.01.015
Authors: Valentina Tateo, Giuseppe Basile, Patrizia Giannatempo, Joep J. de Jong, James A. Proudfoot, Brigida A. Maiorano, Antonio Cigliola, Chiara Mercinelli, Elai Davicioni, Marco Moschini, Giovanni Tremolada, Simone Rota, Giorgio Brembilla, Maurizio Colecchia, Francesco De Cobelli, Francesco Montorsi, Andrea Necchi
Institutions: IRCCS Ospedale San Raffaele, Fondazione IRCCS Istituto Nazionale dei Tumori, Erasmus MC, Veracyte (United States), IRCCS San Raffaele Roma, Vita-Salute San Raffaele University
Language: English

Topic: Bladder and Urothelial Cancer Treatments
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Keywords: muscle-invasive bladder cancer, pembrolizumab, neoadjuvant immunotherapy, radical cystectomy, five-year survival, event-free survival, pathological response, claudin-low subtype, recurrence-free survival, cisplatin-ineligible patients, de-escalation, predictive biomarkers
SDG: Good health and well-being

Open Access status: green
OpenAlex ID: W7127082107
FWCI: 69.01
Cites: 13
Cited by: 16
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms